Medica RCP |Javlor 50mg | Indications | Side Effects | Composition | Route | all.price

Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » Javlor 50mg

Contraindicated
Embryotoxic and teratogenic in animals

Contraindicated

Javlor 50mg :
Type	Medicine Non Marketed
Originator	B
Agent	Mersaco
Distributor	Mersaco
Laboratory	Pierre Fabre Médicament
Responsible Party	Pierre Fabre Medicament
Origin	France
Manufacturer	Fareva
Origin	France
ATC	L01CA05

Javlor 50mg :

Injectable

Intravenous

Javlor 50mg :

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L01C Plant alkaloids and other natural products

L01CA Vinca alkaloids and analogues

L01CA05 Vinflunine

Javlor 50mg :

Vinflunine : 50mg/2ml

Javlor 50mg :

Transitional cell carcinoma of the urothelial tract 320mg/m² every 3 weeks

Javlor 50mg :

Water for injections

* Excipient with known effect

Hazard Level
◼ Major
◼ Moderate
◼ Minor
◼ Safe

Javlor 50mg :

Revision Date : 19/06/2014

Frequency	Percentage
Very Common	≥ 1/10
Common	≥ 1/100 - < 1/10
Uncommon	≥ 1/1,000 - < 1/100
Rare	≥ 1/10,000 - < 1/1,000
Very Rare	< 1/10,000
Unknown	Cannot be Estimated

Effect	Frequency
Abdominal pain	Very Common
Acute respiratory distress syndrome	Uncommon
Alopecia	Very Common
Anaemia	Very Common
Arthralgia (Pain joint) (Joint ache)	Common
Asthenia	Very Common
Back pain	Common
Bacterial infection	Common
Bone pain	Common
Bronchospasm	Not known
Chest pain	Common
Chills	Common
Constipation	Very Common
Cough	Common
Decreased appetite	Very Common
Dehydration	Common
Diarrhoea (Diarrhea)	Very Common
Dizziness	Common
Dry skin	Uncommon
Dysguesia (taste perversion) (Taste abnormality) (Taste disturbance)	Common
Dyspepsia	Common
Dysphagia	Common
Dyspnoea (dyspnea)	Common
ECG QT prolonged	Not known
Erythema	Uncommon
Extravasation	Uncommon
Fatigue	Very Common
Febrile neutropenia (Neutropenic fever)	Common
Fungal infection	Common
Gastric disorder	Uncommon
Gingival disorder	Uncommon
Headache	Common
Hyperhidrosis	Common
Hypersensitivity	Common
Hypertension	Common
Hyponatraemia (Hyponatremia)	Very Common
Hypotension	Common
Ileus	Common
Inappropriate antidiuretic hormone secretion (SIADH)	Uncommon
Injection site reaction	Very Common
Insomnia	Common
Jaw pain	Common
Laryngeal pain	Uncommon
Leucopenia (Leukopenia)	Very Common
Muscle weakness	Common
Musculoskeletal pain	Common
Myalgia	Very Common
Myocardial infarction	Uncommon
Myocardial ischaemia	Uncommon
Nausea	Very Common
Neuralgia	Common
Neuropathy peripheral	Common
Neutropenia	Very Common
Neutropenic infection	Common
Neutropenic sepsis	Uncommon
Odynophagia	Uncommon
Oedema	Common
Oesophagitis	Uncommon
Oral disorder	Common
Otalgia (Earache) (Ear pain)	Common
Pain	Common
Pain in extremity (Pain in limb)	Common
Peripheral motor neuropathy	Uncommon
Peripheral sensory neuropathy	Very Common
Phlebitis	Common
Posterior reversible leukoencephalopathy syndrome (PRES)	Rare
Pruritus	Common
Pyrexia	Very Common
Renal failure	Uncommon
Skin rash	Common
Stomatitis	Very Common
Syncope	Common
Tachycardia	Common
Thrombocytopenia (Thrombopenia)	Very Common
Tinnitus	Uncommon
Transaminases increased	Uncommon
Tumour pain	Uncommon
Urticaria	Common
Venous thrombosis	Common
Vertigo	Uncommon
Viral infection	Common
Visual disturbance	Uncommon
Vomiting	Very Common
Weight decreased (Weight loss)	Very Common
Weight increased (weight gain)	Uncommon

Javlor 50mg :

Abu Dhabi

Czech Republic

Denmark

Finland

France

Germany

Greece

Iceland

Italy

Norway

Portugal

Spain

The Netherlands

Turkey

Coming Very Soon

Javlor 50mg
MoH 6162

Different Units By MoH Code

Javlor 50mg MoH 6162 :

Form Concentrate for solution for infusion

Packaging Vial (Type I Glass)

Package Size 1x2ml

Strength 50mg/2ml

NSSF ✘

Quarantine ✔

Reg. Number 167733/10

Submission date 01/01/2010

Registration Year 2011

Archived Date 13/06/2024

Price Comparison

You have to register to view this info

Note

You have to register to view this info

Note

Prices are provided in Dollar ($)

You have to register to view this info

Visitors Count: 30971257

Form	Concentrate for solution for infusion
Packaging	Vial (Type I Glass)
Package Size	1x2ml
Strength	50mg/2ml
NSSF	✘
Quarantine	✔
Reg. Number	167733/10
Submission date	01/01/2010
Registration Year	2011
Archived Date	13/06/2024